Navigation Links
Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
Date:6/9/2011

dates; and (vi) the Company will be able to progress its product candidates that are undergoing preclinical testing, including the Neo-Kidney Augment, into clinical trial and (vii) the Company will be able to obtain the capital it needs to develop its product candidates and continue its operations.  For additional factors which could cause actual results to differ from expectations, reference is made to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.  The forward looking statements in this release are made only as of the date hereof and the Company disclaims any intention or responsibility for updating predictions or expectations in this release.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
2. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
3. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
4. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
5. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
8. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
9. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
10. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 The Pharmaceutical Care Management ... managers (PBMs), today filed a lawsuit in ... Iowa law that restricts tools ... the state,s employers and consumers.  The ... severely restricting the use of Maximum Allowable Cost (MAC) ...
(Date:9/2/2014)... Spanien und CALGARY, Alberta , September ... Vorgestellt in der "State of the Art and Featured ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, ... bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 ... gehalten hat. In seinem Vortrag mit dem Titel " ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... June 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) today announced results from a ... BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall ... that produce insulin.) Three years of BYETTA therapy improved ...
... June 25 Novo Nordisk today presented phase 2 ... which demonstrated the potential to help achieve target glycemic control when ... at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1) ... These ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 2Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 3
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Melatonin supplements did not reduce ... a new study found. Many older hospital patients ... to disruption of their normal sleep-wake cycle. A lack ... contributes to delirium, but there has been little research ... This study included 378 patients, average age 84, who ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
(Date:9/2/2014)... Albany, New York (PRWEB) September 02, 2014 ... lucrative business with products and services such as ... color, radio frequency-device based treatments, and breast augmentation ... market report published by U.S.-based market intelligence firm ... anti-aging treatments and products will grow to USD ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3
... now has nearly 400 million hectares of natural grassland, the ... its usable grassland has degraded to various extents and hence ... efforts to protect the country's grasslands. ,He said ... sustainable economic growth. , This is mainly done ...
... As a normal charge contraceptives have a VAT of 17.5% ... and other contraceptives in the ensuing budget.,Gordon Brown is due ... said by High Street chemist Superdrug which said that it ... to 5%. It said the move followed a successful 10-month ...
... - The radiation watchdog in Finland has decided to test ... human proteins by testing them directly on human skin in ... health.// ,A pilot study that is scheduled to ... skin on the participants' arms to cell phone radiation for ...
... product of rice processing, called rice bran, significantly lowers ... humans.// ,Journal of Agricultural and Food Chemistry, ... scientific society holds the nuances of the study. ... Brewing researchers’ showed that if rice ran is added ...
... motivator has been helping South Africans to improve their lives ... workshops in various cities seek to teach// people how to ... says lies between the conscious state and sleep. ... 10 percent of their mind power," Adhia told students at ...
... reported that women in India are gradually becoming more ... 40 percent of India’s infected population//. ,"Women ... disparities, lack of education and trafficking of women are ... the women's human rights and human security unit, United ...
Cached Medicine News:Health News:Biologically Women Are More Vulnerable To HIV Infection 2
Used to introduce large devices for vascular intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Portless Sheath Introducers...
Medicine Products: